Viking Therapeutics, Inc. (VKTX) financial statements (2021 and earlier)

Company profile

Business Address 12340 EL CAMINO REAL, SUITE 250
SAN DIEGO, CA 92130
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments27628829329930230435
Cash and cash equivalents83119142517035
Short-term investments267257274284277135 
Other undisclosed current assets811012110
Total current assets:284289294299302307144
Noncurrent Assets
Operating lease, right-of-use asset11  
Deposits noncurrent assets00000  
Other undisclosed noncurrent assets0011000
Total noncurrent assets:1111000
TOTAL ASSETS:284290294300302307144
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6655554
Accounts payable2222111
Accrued liabilities4433443
Debt00     
Other undisclosed current liabilities  00   
Total current liabilities:7665554
Noncurrent Liabilities
Long-term debt and lease obligation00     
Operating lease, liability00  
Liabilities, other than long-term debt    0  
Deferred rent credit    0  
Other undisclosed noncurrent liabilities  11   
Total noncurrent liabilities:00110  
Total liabilities:7766554
Stockholders' equity
Stockholders' equity attributable to parent277283288295298302140
Common stock0000000
Additional paid in capital406405404402401400232
Accumulated other comprehensive income (loss)000(0)(0)(0)(0)
Accumulated deficit(129)(121)(116)(108)(103)(98)(91)
Total stockholders' equity:277283288295298302140
TOTAL LIABILITIES AND EQUITY:284290294300302307144

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Gain (loss) on disposition of assets for financial service operations 0 (0)   
Gross profit: 0     
Operating expenses(9)(7)(10)(7)(7)(7)(7)
Other undisclosed operating income (loss) (0) 0   
Operating loss:(9)(7)(10)(7)(7)(7)(7)
Nonoperating income1222210
Investment income, nonoperating(0)  00  
Other nonoperating income1222210
Loss from continuing operations before income taxes:(8)(6)(8)(5)(5)(7)(7)
Other undisclosed income from continuing operations8   9  
Income (loss) before gain (loss) on sale of properties:(0)(6)(8)(5)4(7)(7)
Other undisclosed net loss(7)  (0)(9)  
Net loss available to common stockholders, diluted:(7)(6)(8)(5)(5)(7)(7)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(7)(6)(8)(5)(5)(7)(7)
Comprehensive loss:(7)(6)(8)(5)(5)(7)(7)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)(0)00(0)0(0)
Comprehensive loss, net of tax, attributable to parent:(8)(6)(7)(5)(6)(7)(7)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: